Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

M. Beer, Tomasz; J. Armstrong, Andrew; E. Rathkopf, Dana; Loriot, Yohann; N. Sternberg, Cora; S. Higano, Celestia; Iversen, Peter; Bhattacharya, Suman; Carles, Joan; Chowdhury, Simon; D. Davis, Ian; S. de Bono, Johann; P. Evans, Christopher; Fizazi, Karim; M. Joshua, Anthony; Kim, Choung‐Soo; Kimura, Go; N. Mainwaring, Paul; H. Mansbach, Harry; Miller, Kurt; B. Noonberg, Sarah; Perabo, Frank; Phung, De; Saad, Fred; I. Scher, Howard; Taplin, Mary‐Ellen; Venner, Peter; Tombal, Bertrand

doi:10.1056/nejmoa1405095

Public

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Published in New England Journal of Medicine • Jun 1, 2014

Authors:

Tomasz M. Beer

Andrew J. Armstrong

Dana E. Rathkopf

Abstract

BACKGROUND: Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not receive...

Subject

Enzalutamide

Prostate cancer

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!